EarningsPacific Biosciences reported strong 2Q results that came in ahead of street expectations, driven by strong instrument placements despite a challenging macroenvironment.
Operational EfficiencyManufacturing and operational efficiencies continue ahead of plan, with gross margin guide raised and operational expenses lowered.
Product LaunchNew launch Vega performed well and clinical long-read opportunities are being realized, opening up an opportunity.